论文部分内容阅读
目的观察中药糖络宁对糖尿病大鼠血清胰岛素样生长因子-1(IGF-1)含量及肝组织IGF-1基因表达的影响。方法采用链脲佐菌素(STZ)诱导糖尿病大鼠模型,造模成功后随机分为模型组、西药组(依帕司他)、中药糖络宁组,共给药12周,给药结束后,用ELISA法测定大鼠血清IGF-1含量,用RT-PCR法测定大鼠肝组织IGF-1基因表达。结果与正常组大鼠比较,模型组大鼠血清IGF-1含量明显下降、肝组织中IGF-1 mRNA表达明显下调(P<0.01);与模型组大鼠比较,西药组和糖络宁组大鼠血清中IGF-1含量明显增高(P<0.01或P<0.05),糖络宁组与西药组比较也有显著差异(P<0.01);与模型组大鼠比较,糖络宁组和西药组可提高大鼠肝组织中IGF-1 mRNA的表达(P<0.01)。结论糖络宁可提高糖尿病大鼠血清IGF-1水平,上调糖尿病大鼠肝脏IGF-1 mRNA表达。这可能是糖络宁治疗糖尿病周围神经病变的机制。
Objective To observe the effect of Tangduoning on the serum insulin-like growth factor-1 (IGF-1) content and the expression of IGF-1 gene in hepatic tissue of diabetic rats. Methods Diabetic rat models were induced by streptozotocin (STZ). After successful modeling, the rats were randomly divided into model group, western medicine group (Epalrestat), and traditional Chinese medicine Tangluoning group. They were co-administered for 12 weeks. After the determination of IGF-1 in rat serum by ELISA, the expression of IGF-1 gene in rat liver was determined by RT-PCR. Results Compared with the normal group, the serum IGF-1 level in the model group significantly decreased, and the IGF-1 mRNA expression in the liver tissue was significantly down-regulated (P<0.01). Compared with the model group rats, the western medicine group and the caninolone group The serum IGF-1 level was significantly higher in rats (P<0.01 or P<0.05), and there was also a significant difference between the Jinluoning group and the Western medicine group (P<0.01). Compared with the model group rats, the Jinluoning group and the western medicine The group can increase the expression of IGF-1 mRNA in rat liver (P<0.01). Conclusion Dangduoning can increase serum IGF-1 level in diabetic rats and upregulate IGF-1 mRNA expression in diabetic rats. This may be the mechanism of Dunoldin in the treatment of diabetic peripheral neuropathy.